Viking Therapeutics Stock News

Viking Therapeutics is a clinical-stage biotechnology company developing a weight management candidate. Viking Therapeutics' weight management candidate, VK2735 is similar to the active ingredient in

Viking Therapeutics is a clinical-stage biotechnology company developing a weight management candidate. Viking Therapeutics' weight management candidate, VK2735 is similar to the active ingredient in

Viking Therapeutics may be on the verge of a breakthrough obesity care treatment. Right now, obesity care and diabetes are dominated by Novo Nordisk and Eli Lilly.

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as El

The Russell 2000 index offers investors various small-cap companies that can incite great long-term returns and add a more differentiated investment to their portfolio. Not all stocks in the Russell 2

Excitement over its weight-loss drug candidate has made the stock a hot buy this year. Last week, the shares got a further boost from clinical trial data for a pill version of VK2735.

Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.

The biotech concluded an encouraging early-stage trial of its weight-loss drug candidate. It successfully tested a tablet version of the treatment.

The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i

Despite the general fears that the retaining of high interest rates could spark a recession and severely damage the stock market, the situation has been the opposite for the most part in 2024.

Viking's impressive gains are due to excitement about its experimental obesity drug VK2735. The company also has other promising programs in its pipeline.

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Viking Therapeutics Inc.'s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data from the company's early trial of an oral weight-loss treatment — the lat

The 'Fast Money' traders weigh in on Viking Thera stock soaring on its obesity pill data.